The tweet was deleted by the author.
But we saved everything 🙂.
Nautilus Biotechnology announced its expected participation in SEEDS, a research consortium funded by the Advanced Research Projects Agency for Health (ARPA-H). The consortium is co-led by the Buck Institute and Georgetown and aims to study how disease-causing proteins misfold before irreversible cellular damage occurs.
This collaboration highlights Nautilus Biotechnology's commitment to advancing protein research in the biomedical field by contributing its proprietary measurement technology to cutting-edge health research initiatives.
View post on X Loading...
Nautilus Biotechnology recently invited researchers to apply for an oncology grant to analyze AKT1 or EGFR proteoforms in 12 samples at no cost, according to a company announcement. The company has also detailed its Iterative Mapping method for profiling tau proteoforms in a new video based on its Nature Methods research. These initiatives reflect ongoing efforts to expand access to advanced protein measurement technologies.